EXCLUSIVE LIFE SCIENCE FEATURE
REPORT
10
LIFESCIENCELEADER.COM JULY 2014 CMO SUPPLEMENT
The latest industry trends and proprietary data from Nice Insight survey results.
■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma
■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma
■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma
of respondents will consider CMOs in
emerging markets for manufacturing projects
of respondents are already working with CMOs in
emerging markets on manufacturing projects
of respondents say the quality level is too
risky to offshore manufacturing projects
The Percentage by Buyer Group Who
Believe the Quality Level Is Too Risky to
Offshore Oncology Projects
45%
64%
26%
37%
34%
15%
8%
14%
18%
13%
76%
89%
74%
69%
72%
Development
Services
The Percentage by Buyer Group Who Are
Already Working With CMOs in Emerging
Markets on Oncology Projects
Respondents Who Outsource Oncology
Projects and Consider CMOs in Emerging
Markets by Buyer Group
■ Large Molecule API / Biologics
■ Small Molecule API
■ Injectables Product Development
■ Solid Dose, Semi-Solids, & Liquid Development
■ Other Delivery Forms (Inhalable / Transdermal)
64% 60% 58% 52% 24%
■ Large Molecule API / Biologics
■ Small Molecule API & Advanced Intermediates
■ Solid Dosage Forms
■ Injectables
■ Semi-Solids & Liquids
■ Specialty Dosage Forms
Manufacturing
Services
49% 38% 59% 54% 47% 46%
0 7 1 4 _ R e s e a r c h _ R e p o r t s _ O I _ O n c o l o g y 2 . i n d d 3 0714_Research_Reports_OI_Oncology2.indd 3 6 / 2 0 / 2 0 1 4 1 0 : 3 0 : 0 0 A M 6/20/2014 10:30:00 AM